|

Chimeric Antigen Receptor T-Cell Therapy Clinical Trials

7 actively recruiting trials across 5 locations

Also known as: Axi-Cel, CAR T Infusion, CAR T Therapy, CAR T-cell Therapy, Chimeric Antigen Receptor T-cell Infusion, Yascarta

Duarte, California2 trials

Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma

City of Hope Medical Center

Early 1
Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma

City of Hope Medical Center

Phase 1

Sacramento, California2 trials

Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

University of California Davis Comprehensive Cancer Center

Phase 1
Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy

University of California Davis Comprehensive Cancer Center

Phase 2

Scottsdale, Arizona1 trial

Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy

Mayo Clinic in Arizona

Phase 2

Tampa, Florida1 trial

Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL

Moffitt Cancer Center

Phase 2

Seattle, Washington1 trial

Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T

Fred Hutch/University of Washington Cancer Consortium

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.